As of 2026-10-12, the Intrinsic Value of Algernon Pharmaceuticals Inc (AGN.CN) is -1.21 CAD. This AGN.CN valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.36 CAD, the upside of Algernon Pharmaceuticals Inc is -441.65%.
Based on its market price of 0.36 CAD and our intrinsic valuation, Algernon Pharmaceuticals Inc (AGN.CN) is overvalued by 441.65%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -1.21 - -1.21 | -1.21 | -441.65% |
| P/E | (0.01) - 0.12 | 0.07 | -80.2% |
| DDM - Stable | (5.30) - 11.64 | 3.17 | 792.4% |
| DDM - Multi | (4.72) - 8.20 | (23.00) | -6577.7% |
| Market Cap (mil) | 3.17 |
| Beta | -0.27 |
| Outstanding shares (mil) | 8.92 |
| Enterprise Value (mil) | 2.96 |
| Market risk premium | 5.10% |
| Cost of Equity | 4.59% |
| Cost of Debt | 5.00% |
| WACC | 4.14% |